Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab retreatment and maintenance in relapsed CLL after prior response/stable disease in Hx-CD20-406
2008-001507-39Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by GSK. Primary endpoint: Proportion of objective responders. Started Sep 2008; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-001507-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001507-39.